Health Care & Life Sciences » Pharmaceuticals | IntelGenx Technologies Corp.

IntelGenx Technologies Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,639.00
1,746.00
1,291.00
1,180.00
3,051.00
10,108
Depreciation, Depletion & Amortization
72.00
74.00
171.00
511.00
735.00
719
Other Funds
517.00
-
-
-
-
1,141
Funds from Operations
1,453.00
1,571.00
1,592.00
474.00
1,878.00
8,248
Changes in Working Capital
280.00
191.00
540.00
2,405.00
2,505.00
282
Net Operating Cash Flow
1,173.00
1,380.00
1,052.00
1,931.00
4,383.00
8,530
Capital Expenditures
266.00
403.00
3,380.00
2,326.00
973.00
Purchase/Sale of Investments
-
-
-
3,584.00
766.00
Net Investing Cash Flow
266.00
403.00
3,380.00
5,910.00
207.00
Issuance/Reduction of Debt, Net
-
-
1,730.00
1,265.00
4,270.00
Net Financing Cash Flow
4,479.00
1,619.00
1,792.00
1,924.00
5,508.00
Net Change in Cash
2,946.00
606.00
1,028.00
2,051.00
979.00
Free Cash Flow
1,439.00
1,783.00
2,328.00
395.00
5,356.00
Change in Capital Stock
4,996.00
1,619.00
62.00
659.00
1,238.00
Exchange Rate Effect
94.00
442.00
492.00
4.00
61.00

About IntelGenx Technologies

View Profile
Address
6420 Abrams
Ville Saint-Laurent Québec H4S 1X9
Canada
Employees -
Website http://www.intelgenx.com
Updated 07/08/2019
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast. It also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research and development, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.